A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Clinical trial NCT04449874 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04449874
- Sponsor
- Genentech, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-29
- Primary completion
- 2027-12-31
- Enrollment
- 498
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.